Revumenib Shows Promise for Advanced Acute Myeloid Leukemia
Apr 18, 2023 — A new type of targeted therapy shows promise for acute myeloid leukemia (AML), one of the most difficult leukemias to treat. The drug, revumenib, is part of a group, or class, of drugs known as menin inhibitors.
Latest advancements in treatment for acute myeloid leukemia
Mar 2, 2023 — Acute myeloid leukemia, also called acute myelogenous leukemia (AML), is the most common type of acute leukemia in adults, and it can progress quickly if not treated. Chemotherapy can sometimes successfully treat AML, but new treatments and tailored chemotherapy approaches are helping even more people achieve remission.
Acute Myeloid Leukemia | Oncology & Cancer News | CURE
CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.
Moleculin Accelerates Planned Unblinded Data Readout for …
16 hours ago — Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the European Medicines Agency (EMA). About Moleculin Biotech, Inc.
NIH clinical trial will test precision medicine treatments for myeloid ...
Oct 23, 2024 — The National Institutes of Health (NIH) has launched a proof-of-concept precision medicine clinical trial to test new treatment combinations targeting specific genetic changes in the cancer cells of people with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Study Highlights Promising New Treatment Option for Patients …
Sep 30, 2024 — Results especially promising in patients with high-risk leukemia subtypes. BUFFALO, N.Y. — The Clinical Leukemia Service at Roswell Park Comprehensive Cancer Center helped lead the first clinical trial of the experimental oral drug ziftomenib in patients with acute myeloid leukemia (AML).
FDA Approves New Targeted Treatment for Acute Myeloid Leukemia
Rye Brook, N.Y., July 25, 2023 – The U.S. Food and Drug Administration (FDA) last week approved quizartinib (Vanflyta®) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that carries a genetic mutation called FLT3-ITD.
New CAR T Cell Clinical Trial for Acute Myeloid Leukemia Is First …
Apr 22, 2024 — Sadelain’s team published results in Cancer Cell in October 2023, showing that a new type of CAR T cell could selectively destroy AML cells in mice without causing toxic side effects. The CAR T cells target two antigens at once.
Acute myeloid leukemia: current progress and future directions
Feb 22, 2021 — Abstract. Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in...
Moleculin Receives Institutional Review Board Approval for …
2 days ago — Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the European Medicines Agency (EMA). About Moleculin Biotech, Inc.